| Code | CSB-RA872537MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Avizakimab, targeting interleukin-21 (IL-21), a pleiotropic cytokine primarily produced by activated CD4+ T cells, natural killer T cells, and T follicular helper cells. IL-21 plays critical roles in regulating immune responses by promoting B cell differentiation, enhancing cytotoxic T cell and NK cell functions, and modulating inflammatory pathways. Dysregulated IL-21 signaling has been implicated in various autoimmune and inflammatory conditions, including inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, making it an important therapeutic target for immune-mediated disorders.
Avizakimab is a humanized monoclonal antibody designed to neutralize IL-21 activity by blocking its interaction with the IL-21 receptor. This biosimilar antibody provides researchers with a valuable tool for investigating IL-21-mediated immune mechanisms, studying cytokine signaling networks, and exploring potential therapeutic interventions in autoimmune disease models. It enables detailed examination of IL-21's role in immune cell activation, differentiation, and effector functions across various experimental systems.
There are currently no reviews for this product.